Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Philippe Bernard

Showing results (91-100 of 135) with videos related to

Pageof 14
Sort By:
Dermatology (Basel, Switzerland)|September 8, 2007
Neurological disorders in patients with bullous pemphigoidNadège Cordel, Olivier Chosidow, Marie-France Hellot, et al.
Scientific Reports|December 15, 2015
Integrating longitudinal serum IL-17 and IL-23 follow-up, along with autoantibodies variation, contributes to predict bullous pemphigoid outcomeJulie Plée, Sébastien Le Jan, Jérôme Giustiniani, et al.
The Journal of Investigative Dermatology|June 20, 2014
Innate immune cell-produced IL-17 sustains inflammation in bullous pemphigoidSébastien Le Jan, Julie Plée, David Vallerand, et al.
The Journal of Investigative Dermatology|March 16, 2012
Incidence and mortality of bullous pemphigoid in FrancePascal Joly, Sophie Baricault, Agnès Sparsa, et al.
Journal of the American Academy of Dermatology|December 18, 2007
Comparison of histopathologic-clinical characteristics of Jessner's lymphocytic infiltration of the skin and lupus erythematosus tumidus: Multicenter study of 46 casesValérie Rémy-Leroux, Fabienne Léonard, Daniel Lambert, et al.
International Journal of Cosmetic Science|February 8, 2024
Randomized double-blind placebo-controlled cosmetic trial of a topical first-in-class Neutraligand targeting the chemokine TARC/CCL17 in mild-to-moderate atopic dermatitisNelly Frossard, Alexandra Coïc, Thibaut Saguet, et al.
Scientific Reports|October 8, 2015
A strategy to discover decoy chemokine ligands with an anti-inflammatory activityDayana Abboud, François Daubeuf, Quoc Tuan Do, et al.
JAMA Dermatology|November 15, 2013
Clinical and immunologic factors associated with bullous pemphigoid relapse during the first year of treatment: a multicenter, prospective studyFanny Fichel, Coralie Barbe, Pascal Joly, et al.
Haematologica|February 14, 2007
New types of MYST3-CBP and CBP-MYST3 fusion transcripts in t(8;16)(p11;p13) acute myeloid leukemiasAnne Murati, José Adélaïde, Benoît Quilichini, et al.
The Journal of Investigative Dermatology|June 4, 2004
BP230- and BP180-specific auto-antibodies in bullous pemphigoidSybille Thoma-Uszynski, Wolfgang Uter, Susanne Schwietzke, et al.
Pageof 14

Showing results (91-100 of 135) with videos related to

Sort By:
Pageof 14
Dermatology (Basel, Switzerland)|September 8, 2007
Neurological disorders in patients with bullous pemphigoidNadège Cordel, Olivier Chosidow, Marie-France Hellot, et al.
Scientific Reports|December 15, 2015
Integrating longitudinal serum IL-17 and IL-23 follow-up, along with autoantibodies variation, contributes to predict bullous pemphigoid outcomeJulie Plée, Sébastien Le Jan, Jérôme Giustiniani, et al.
The Journal of Investigative Dermatology|June 20, 2014
Innate immune cell-produced IL-17 sustains inflammation in bullous pemphigoidSébastien Le Jan, Julie Plée, David Vallerand, et al.
The Journal of Investigative Dermatology|March 16, 2012
Incidence and mortality of bullous pemphigoid in FrancePascal Joly, Sophie Baricault, Agnès Sparsa, et al.
Journal of the American Academy of Dermatology|December 18, 2007
Comparison of histopathologic-clinical characteristics of Jessner's lymphocytic infiltration of the skin and lupus erythematosus tumidus: Multicenter study of 46 casesValérie Rémy-Leroux, Fabienne Léonard, Daniel Lambert, et al.
International Journal of Cosmetic Science|February 8, 2024
Randomized double-blind placebo-controlled cosmetic trial of a topical first-in-class Neutraligand targeting the chemokine TARC/CCL17 in mild-to-moderate atopic dermatitisNelly Frossard, Alexandra Coïc, Thibaut Saguet, et al.
Scientific Reports|October 8, 2015
A strategy to discover decoy chemokine ligands with an anti-inflammatory activityDayana Abboud, François Daubeuf, Quoc Tuan Do, et al.
JAMA Dermatology|November 15, 2013
Clinical and immunologic factors associated with bullous pemphigoid relapse during the first year of treatment: a multicenter, prospective studyFanny Fichel, Coralie Barbe, Pascal Joly, et al.
Haematologica|February 14, 2007
New types of MYST3-CBP and CBP-MYST3 fusion transcripts in t(8;16)(p11;p13) acute myeloid leukemiasAnne Murati, José Adélaïde, Benoît Quilichini, et al.
The Journal of Investigative Dermatology|June 4, 2004
BP230- and BP180-specific auto-antibodies in bullous pemphigoidSybille Thoma-Uszynski, Wolfgang Uter, Susanne Schwietzke, et al.
Pageof 14